Verrica Pharmaceuticals (VRCA)
(Delayed Data from NSDQ)
$6.87 USD
+0.22 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $6.85 -0.02 (-0.29%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Income Statements
Fiscal Year end for Verrica Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 5 | 9 | 12 | 0 | 0 |
Cost Of Goods | 1 | 1 | 0 | 0 | 0 |
Gross Profit | 4 | 8 | 12 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 70 | 30 | 43 | 40 | 30 |
Income After Depreciation & Amortization | -66 | -21 | -31 | -40 | -30 |
Non-Operating Income | 3 | -1 | 0 | 1 | 2 |
Interest Expense | 4 | 2 | 4 | 3 | 0 |
Pretax Income | -67 | -24 | -35 | -43 | -28 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -67 | -24 | -35 | -43 | -28 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -67 | -24 | -35 | -43 | -28 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -65 | -20 | -30 | -40 | -30 |
Depreciation & Amortization (Cash Flow) | 1 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -66 | -21 | -31 | -40 | -30 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 45.34 | 34.16 | 27.05 | 25.00 | 24.90 |
Diluted EPS Before Non-Recurring Items | -1.14 | -0.66 | -1.25 | -1.71 | -1.13 |
Diluted Net EPS (GAAP) | -1.48 | -0.72 | -1.30 | -1.71 | -1.13 |
Fiscal Year end for Verrica Pharmaceuticals Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 1.99 | 2.92 | 0.18 | 0.04 |
Cost Of Goods | NA | 0.27 | 0.27 | 0.14 | 0.07 |
Gross Profit | NA | 1.72 | 2.65 | 0.05 | -0.03 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.32 | 26.56 | 11.67 | 7.06 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -20.60 | -23.91 | -11.62 | -7.09 |
Non-Operating Income | NA | 0.83 | 0.77 | 0.63 | 0.50 |
Interest Expense | NA | 2.31 | 1.66 | 0.00 | 0.00 |
Pretax Income | NA | -24.61 | -24.80 | -10.99 | -6.59 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -24.61 | -24.80 | -10.99 | -6.59 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -24.61 | -24.80 | -10.99 | -6.59 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 46.31 | 46.07 | 45.92 | 43.02 |
Diluted EPS Before Non-Recurring Items | NA | -0.48 | -0.32 | -0.24 | -0.15 |
Diluted Net EPS (GAAP) | NA | -0.55 | -0.54 | -0.24 | -0.15 |